Pacira BioSciences (NASDAQ:PCRX) Issues Quarterly Earnings Results

Pacira BioSciences (NASDAQ:PCRX) announced its earnings results on Thursday. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01), FiscalAI reports. Pacira BioSciences had a return on equity of 9.99% and a net margin of 0.70%.The firm had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. During the same quarter in the prior year, the firm posted $0.65 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year.

Here are the key takeaways from Pacira BioSciences’ conference call:

• EXPAREL is showing renewed momentum with Q1 net sales of $143.3M (volume ~+7% YoY), expanded reimbursement outside the surgical bundle to >110 million covered lives, a new product-specific J-code, and strengthened IP protection with 21 Orange Book-listed patents.
• PCRX-201 (HCAd gene therapy for knee OA) is on a catalyst-rich path — Part A top-line (safety-focused) due later this year and Part B ~90-patient enrollment planned mid-year — but efficacy is early-stage and the program remains high-risk/high-reward.
• Early-intervention portfolio traction — Zilretta sales rose ~15% in Q1 with Phase III shoulder OA enrollment complete (top-line later this year), and iovera sales rose ~21% with a registrational spasticity readout expected by year-end.
• Management reiterated full-year 2026 guidance (total revenues $745–$770M, EXPAREL sales $600–$620M), reported strong adjusted EBITDA (~$40.2M in Q1), ended the quarter with $202M cash, and executed another $50M share repurchase (≈9M shares retired to date), supporting capital-return and financial flexibility.
• Near-term headwinds include revenue pressure from vial-mix shifts and GPO-driven discounting, Q1 shipping/return disruptions from winter storms, elevated SG&A tied to proxy activities, and policy uncertainty as the NOPAIN Act is currently set to expire in 2027.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX opened at $24.44 on Friday. The company has a 50 day simple moving average of $23.31 and a two-hundred day simple moving average of $23.14. The stock has a market cap of $989.58 million, a price-to-earnings ratio of 162.93 and a beta of 0.19. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $27.64.

Analysts Set New Price Targets

A number of research firms recently commented on PCRX. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays reduced their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 26th. Needham & Company LLC raised their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Finally, Royal Bank Of Canada increased their price target on Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research note on Friday. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and a consensus price target of $29.40.

Pacira BioSciences News Roundup

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Needham & Company raised its price target to $32 and maintained a Buy rating — this implies ~31.7% upside from the recent price and serves as a strong bullish analyst catalyst for investors focused on upside potential. Needham PT Raise
• Positive Sentiment: Q1 results beat expectations: revenue of ~$177M (+5% YoY) and EPS of $0.60 topped consensus, driven by commercial portfolio growth (including EXAPAREL volume growth). That operational beat supports near-term revenue trajectory and validates current demand. Q1 Press Release
• Positive Sentiment: Pipeline progress: Pacira advanced PCRX-201 into Phase II and completed enrollment in a Phase 3 shoulder OA study for ZILRETTA, keeping multiple clinical milestones on the calendar that could drive medium-term upside if readouts are positive. Pipeline & Guidance Summary
• Neutral Sentiment: Royal Bank of Canada raised its price target from $22 to $24 but kept a “sector perform” rating — the PT is only marginally changed relative to the market and signals a cautious stance despite the bump. RBC PT Update
• Neutral Sentiment: Earnings materials and the call highlighted “strong product growth” and provided detail on product mix and market dynamics — helpful context but not an immediate directional shock. Earnings Call Highlights
• Negative Sentiment: FY2026 revenue guidance of $745M–$770M sits slightly under consensus (~$761.5M at the time of the news), leaving the guidance a bit cautious and a potential near-term headwind if investors expected a clearer upside beat. Guidance Article
• Negative Sentiment: Overall market reaction is negative today (heavier-than-normal volume), reflecting investor caution as they reconcile the mixed signals: solid quarter and pipeline news vs. conservative-to-in-line guidance and at least one cautious analyst stance. Market Data

Insider Buying and Selling

In related news, SVP Lauren Riker sold 4,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares in the company, valued at $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jonathan Slonin sold 3,261 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the sale, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. The trade was a 1.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 32,261 shares of company stock valued at $785,850 over the last 90 days. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Large investors have recently bought and sold shares of the company. Vident Advisory LLC raised its holdings in shares of Pacira BioSciences by 15.0% during the fourth quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock valued at $610,000 after acquiring an additional 3,075 shares during the last quarter. Empowered Funds LLC increased its position in shares of Pacira BioSciences by 1.9% during the fourth quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock worth $5,890,000 after purchasing an additional 4,167 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Pacira BioSciences during the fourth quarter worth approximately $2,146,000. Millennium Management LLC raised its stake in Pacira BioSciences by 73.3% in the 4th quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock valued at $3,173,000 after purchasing an additional 51,848 shares during the last quarter. Finally, Inspire Investing LLC lifted its holdings in Pacira BioSciences by 3.2% in the 4th quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after purchasing an additional 556 shares in the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.